Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ticagrelor PK/PD in Hemodialysis Patients vs Healthy Subjects
NCT02022748Phase 1Completed
- Sponsor
- AstraZeneca
- Start
- Dec 2013
- Primary completion
- May 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of ticagrelor in acute coronary syndrome (ACS) (3 arms), sponsored by AstraZeneca. Primary endpoints: Maximum Plasma Concentration (Cmax) of Ticagrelor, Maximum Plasma Concentration (Cmax) of AR-C124910XX and 2 more. Started Dec 2013; status: completed.
02
Drugs
ticagrelor
03
Conditions
acute coronary syndrome (ACS)
Beyond the preview
Go deeper on NCT02022748.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02022748.